For more than 25-years, Bob Mitchell has operated in multiple senior leadership capacities leading high-technology medical device companies. In 2008, he served as President and Chief Executive Officer for Nellix Inc. in Palo Alto California, a privately held medical device company specializing in the endovascular treatment of Abdominal Aortic Aneurysms. In January 2011, Nellix was sold to NASDAQ-listed Endologix Inc. where he was President for 7 years. In January 2018, Mr. Mitchell assumed President Emeritus status for Endologix to dedicate more time to several boards and investments he has made over the years.
In 2005, Mr. Mitchell served as Chief Operating Officer & Executive Vice President of New York based AngioDynamics, a NASDAQ-listed public company and leading provider of innovative medical devices to treat cancer and peripheral vascular disease. During his tenure, he oversaw the acquisition of RITA Medical. Prior to this, Mr. Mitchell served as Chairman, President and Chief Executive Officer of Millimed Holdings, Inc., a privately held company in Roskilde, Denmark, developing next-generation drug eluting products for vascular disease. Much of Mr. Mitchell's professional experience (1986 – 2002) was at Cook Medical Inc., the world’s largest privately held medical device company, where he was accountable for revenues in excess of a billion dollars. As Senior Vice President, living in Bloomington Indiana, he led Cook’s largest revenue generating business units including: interventional radiology, cardiology, endovascular, critical care and surgical. Following his time at Cook, he served as Vice President of Worldwide Sales, Chairman of Align Japan and a member of the Global Executive Management Committee for NASDAQ-listed Align Technology (Invisalign), Inc. of Santa Clara, California.
Mr. Mitchell was a General Partner and co-founder of Summit Life Science Partners, an early stage medical device venture fund based in Park City, UT. He has been an advisor to more than 20 humanitarian and/or healthcare companies serving as a member of the board for several including the American Heart Association (Bloomington, Indiana and Irvine, California), NeoSci International Inc. (Singapore), and HeartFlow Inc. (Stanford University, Palo Alto, California). He is currently chairman of the board for Amecath Inc. (Cairo, Egypt) and PULSE Therapeutics (St. Louis, Mo) and serves on the board for JenaValve Inc. (Irvine, Ca), Adient Technologies (Houston, Tx), Summit Access (Denver, Co) and CSA BioTech (Provo, UT). Throughout his career, Mr. Mitchell has authored and/or coauthored many medical publications, technical papers and clinical presentations. In addition, he has been an invited lecturer in more than 15 countries. Mr. Mitchell received his Bachelor of Science degree in Economics from the University of Utah and his MBA from Wesleyan University (Indiana).